Skip to main content

Table 5 Studies describing hospital length of stay in patients with resistant and multidrug-resistant Pseudomonas aeruginosa infections

From: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author

Study groups (n)

Median (mean) Hospital Length of Stay (days)

Reported Significance (p-value or 95% CI)

Ref

Main findings

Brooklyn Antibiotic Resistance Task Force (2002)*

Carbapenem susceptible P. aeruginosa (10)

20 (17)

0.002 (0.001)

[60]

Carbapenem resistant P. aeruginosa (10)

33.5 (36)

Eagye et al. (2009)*

Meropenem resistant P. aeruginosa (58)

30

<0.001

[53]

Meropenem susceptible P. aeruginosa (125)

16

Meropenem resistant P. aeruginosa (58)

30

<0.001

Control (57)

10

Evans et al. (2007)‡

Susceptible P. aeruginosa (73)

20

0.03

[71]

Resistant P. aeruginosae (47)

26

Furtado et al. (2009)‡

Imipenem resistant P. aeruginosa (63)

25

0.006

[62]

Control (182)

15

Gasink et al. (2006)*

Fluoroquinolone resistant P. aeruginosa (320)

10

0.13

[64]

Fluoroquinolone susceptible P. aeruginosa (527)

9

Kaminski et al. (2011)†

Ureido/carboxypenicillin resistant P. aeruginosa (70)

50

0.24

[66]

Ureido/carboxypenicillin susceptible P. aeruginosa (153)

47.5

Lautenbach et al. (2010)†

Imipenem resistant P. aeruginosa (253)

16

<0.001

[63]

Imipenem susceptible P. aeruginosa (2289)

9

Morales et al. (2012)‡

MDR P. aeruginosaf (134)

39 (45.7)

<0.001a

[49]

Susceptible P. aeruginosa (149)

20 (25.1)

Resistant P. aeruginosa (119)

30 (39.0)

<0.001a

Susceptible P. aeruginosa (149)

20 (25.1)

Paramythiotou et al. (2004)†

MDR P. aeruginosag (34)

44.5 (57.0)b,d/11.1c,d

0.28/0.81

[54]

Control (34)

43.5 (46.9)b,d/5.8c,d

Tam et al. (2010)†

MDR P. aeruginosah (25)

26.4c

0.12

[13]

Susceptible P. aeruginosa (84)

16.5c

  1. *Length of stay reported after identification of infection with P. aeruginosa;†Length of stay reported as total length of stay; ‡Length of stay not defined as total length of stay or length of stay after identification of infection with P. aeruginosa; a P-value reported for mean length of stay; b Length of ICU stay (ICU stay matched between cases and controls); cLength of stay in hospital following ICU discharge; dStudy reported mean length of stay; eAbsence of susceptibility to all the drugs in one or more of the following antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; fAbsence of susceptibility to carbapenems, β-lactams, quinolones, tobramycin, and gentamicin; g Absence of susceptibility to piperacillin, ceftazidime, imipenem, and ciprofloxacin; hAbsence of susceptibility to three or more of the following four classes of agents: antipseudomonal carbapenems, antipseudomonal β-lactams (penicillins and cephalosporins), aminoglycosides, and fluoroquinolones.